Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

William Blair Downgrades 10x Genomics to Market Perform

William Blair analyst Brian Weinstein downgrades 10x Genomics (NASDAQ:TXG) from Outperform to Market Perform.

byBenzinga Newsdesk

July 15, 2022

1 minute read

William Blair analyst Brian Weinstein downgrades 10x Genomics (NASDAQ:TXG) from Outperform to Market Perform.

Tonix Pharmaceuticals Q2 EPS $(0.07) Up From $(0.23) YoY

By Benzinga Newsdesk

Today, 12:23 PM

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.07) per share. This is a 69.57 percent increase over losses of $(0.23) per share from the same period last year.

TNXP

Barclays Maintains Overweight on Datadog, Lowers Price Target to $110

By Benzinga Newsdesk

Today, 12:23 PM

Barclays analyst Raimo Lenschow maintains Datadog (NASDAQ:DDOG) with a Overweight and lowers the price target from $130 to $110.

DDOG

Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $75

By Benzinga Newsdesk

Today, 12:23 PM

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $85 to $75.

BCYC

Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab

By Vandana Singh

Today, 12:23 PM

Amgen Inc (NASDAQ:AMGN) announced new data from the NAVIGATOR Phase 3 trial evaluating tezepelumab in patients who also have nasal polyps,…

AMGN

William Blair Downgrades 10x Genomics to Market Perform

Related Posts

Tonix Pharmaceuticals Q2 EPS $(0.07) Up From $(0.23) YoY

Barclays Maintains Overweight on Datadog, Lowers Price Target to $110

Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $75

Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab